Stereotactic Body Radiotherapy as Treatment for Organ Confined Low and Intermediate Risk Prostate Carcinoma, a Seven Year Study
Objectives: Stereotactic body radiation therapy (SBRT) takes advantage of the prostate’s low α/β ratio to deliver a large radiation dose in few fractions. Initial studies on small groups of low-risk patients support SBRT’s potential for clinical efficacy while limiting treatment-related morbidity an...
Main Authors: | Alan Jay Katz, Josephine eKang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2014-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00240/full |
Similar Items
-
Quality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a Seven Year Study
by: Alan Jay Katz, et al.
Published: (2014-10-01) -
Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer
by: Katz Alan, et al.
Published: (2012-11-01) -
Stereotactic radiotherapy with focal boost for intermediate and high-risk prostate cancer: Initial results of the SPARC trial
by: Luke Nicholls, et al.
Published: (2020-11-01) -
Stereotactic body radiotherapy for localized prostate cancer – 5-year efficacy results
by: Kristiina Vuolukka, et al.
Published: (2020-07-01) -
Editorial: The Evolving Landscape of Stereotactic Body Radiation Therapy for the Management of Prostate Cancer
by: Seth R. Blacksburg, et al.
Published: (2020-12-01)